在治疗Clostridioides difficile感染时,短也更好吗?
M Duricek1, K Halmova1, M Krutova2
1Department of Infectious Diseases, 3rd Faculty of Medicine, Charles University and University Hospital Bulovka, Budínova 67/2, 180 81, Praha 8, Prague, Czech Republic.
The Journal of antimicrobial chemotherapy
|April 25, 2024
概括
缩短的万科米辛或菲达克索米辛疗法有效地治疗了Clostridioides difficile感染 (CDI),与标准的10天治疗相比,复发率较低. 建议进行进一步的研究,以证实Clostridioides difficile感染管理中的这些发现.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 困难菌感染 (CDI) 构成了医疗保健方面的重大挑战.
- 对CDI的标准治疗持续时间可能很长,可能导致副作用和耐药性.
- 优化抗生素治疗方案对于有效的CDI管理至关重要.
研究的目的:
- 评估缩短万科米辛或菲达克索米辛治疗时间的有效性,以治疗Clostridioides difficile感染 (CDI).
- 为了比较缩短和标准的10天治疗方案之间的CDI复发率.
- 评估接受缩短CDI治疗的患者的安全性和临床反应.
主要方法:
- 一项观察性研究包括诊断为CDI的成年患者.
- 患者接受了5天或7天的万科米辛治疗方案或5天的菲达克索米辛治疗方案.
- 对照组接受了标准的10天的万科米辛或菲达克索米辛治疗;随访时间为60天.
主要成果:
- 25名患者接受了缩短的治疗方案 (万科米辛n=21,费达克索米辛n=4),其中8.0%的患者经历了复发性CDI.
- 对照组 (n=22) 的复发率为Clostridioides difficile感染的22.7%.
- 两组之间没有观察到统计学上显著的差异,尽管在缩短疗程组中复发率较低.
结论:
- 缩短的万科米辛和菲达克索米辛治疗方案似乎对Clostridioides difficile感染 (CDI) 有效.
- 该研究观察到,在接受缩短CDI疗程治疗的患者中,复发率较低.
- 需要进行更大规模的前性研究来验证这些研究结果在Clostridioides difficile感染治疗中.
相关概念视频
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
118
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
118
Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
Pulmonary Tuberculosis V
178
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
178
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
379
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
379


